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Abstract 
There is growing interest in defining the aberrant molecular differences between normal and 
tumor-associated fibroblasts (TAFs) that support tumor progression. For this purpose, we 
recently conducted a genome-wide DNA methylation profiling of TAFs and paired control 
fibroblasts (CFs) from non-small cell lung cancer (NSCLC) patients, and reported a 
widespread hypomethylation concomitantly with focal gain of DNA methylation; in addition, 
we found evidence that a fraction of lung TAFs are fibrocytes in origin. Of note, the aberrant 
epigenome of lung TAFs had a global impact in gene expression and a selective impact on 
the TGF-β pathway. To get insights on the functional implications of the latter impact, we 
analyzed the response of lung TAFs to exogenous TGF-β1 in terms of activation and 
contractility. We found a larger expression of a panel of activation markers including α-SMA 
and collagen-I in TAFs compared to control fibroblasts. Likewise, TGF-β1 elicited a larger 
contractility in TAFs than in CFs as assessed by traction force microscopy. These findings 
reveal that lung TAFs are hyperresponsive to TGF-β1, which may underlie the expansion 
and/or maintenance of the tumor-promoting desmoplastic stroma in lung cancer. 
	
